Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 5 (May)

1. Transperineal ultrasound-guided 12-core systematic biopsy of the prostate for patients with a prostate-specific antigen level of 2.5-20 ng/ml in Japan.
   Int J Clin Oncol, 10(2): 117-21. [Abstract] [Full-text]
2. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
   Lancet Oncol, 6(5): 295-300. [Abstract] [Full-text]
3. The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product.
   Cancer Lett, 222(2): 211-5. [Abstract] [Full-text]
4. Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
   Cancer Lett, 222(2): 145-51. [Abstract] [Full-text]
5. Intention to test for prostate cancer.
   Eur J Cancer, 41(7): 990-7. [Abstract] [Full-text]
6. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
   Oncology, 68(1): 2-9. [Abstract] [Full-text]
7. What do cancer survivors believe causes cancer? (United States).
   Cancer Causes Control, 16(2): 115-23. [Abstract] [Full-text]
8. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
   Cancer Res, 65(9): 3707-15. [Abstract] [Full-text]
9. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
   Clin Cancer Res, 11(9): 3353-62. [Abstract] [Full-text]
10. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer.
    Clin Cancer Res, 11(9): 3250-6. [Abstract] [Full-text]
11. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity.
    Clin Cancer Res, 11(9): 3243-9. [Abstract] [Full-text]
12. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
    Clin Cancer Res, 11(9): 3210-6. [Abstract] [Full-text]
13. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells.
    J Androl, 26(3): 422-8. [Abstract] [Full-text]
14. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells.
    Biochim Biophys Acta, 1734(1): 1-12. [Abstract] [Full-text]
15. Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
    Mol Cell Endocrinol, 235(1): 51-61. [Abstract] [Full-text]
16. Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer.
    J Endourol, 19(3): 318-26. [Abstract] [Full-text]
17. 20-year outcomes following conservative management of clinically localized prostate cancer.
    JAMA, 293(17): 2095-101. [Abstract] [Full-text]
18. Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines.
    Urol Oncol, 23(2): 123-9. [Abstract] [Full-text]
19. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.
    Urol Oncol, 23(2): 108-13. [Abstract] [Full-text]
20. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Urol Oncol, 23(2): 93-101. [Abstract] [Full-text]
21. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
    Urol Oncol, 23(2): 87-92. [Abstract] [Full-text]
22. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer.
    Urol Oncol, 23(2): 82-6. [Abstract] [Full-text]
23. The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
    Cancer Biother Radiopharm, 20(2): 189-94. [Abstract] [Full-text]
24. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.
    J Cell Physiol, 204(1): 36-44. [Abstract] [Full-text]
25. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy.
    Cancer, 103(10): 2042-52. [Abstract] [Full-text]
26. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy.
    Cancer, 103(10): 2030-4. [Abstract] [Full-text]
27. Symptomatic local recurrence of prostate carcinoma after radiation therapy.
    Cancer, 103(10): 2060-6. [Abstract] [Full-text]
28. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma.
    Cancer, 103(10): 2053-9. [Abstract] [Full-text]
29. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Cancer Chemother Pharmacol, 56(1): 46-54. [Abstract] [Full-text]
30. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents.
    Oncogene, 24(20): 3328-38. [Abstract] [Full-text]
31. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Adv Drug Deliv Rev, 57(7): 995-1010. [Abstract] [Full-text]
32. A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study.
    J Clin Epidemiol, 58(6): 639-44. [Abstract] [Full-text]
33. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Clin Ther, 27(3): 273-85. [Abstract] [Full-text]
34. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Radiother Oncol, 75(1): 74-82. [Abstract] [Full-text]
35. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies.
    BJU Int, 95(8): 1146-52. [Abstract] [Full-text]
36. Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors.
    Genes Chromosomes Cancer, 43(3): 273-83. [Abstract] [Full-text]
37. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer.
    Genes Chromosomes Cancer, 43(3): 249-59. [Abstract] [Full-text]
38. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells.
    J Biol Chem, 280(19): 18636-42. [Abstract] [Full-text]
39. A prospective study of physical activity and incident and fatal prostate cancer.
    Arch Intern Med, 165(9): 1005-10. [Abstract] [Full-text]
40. An A/G polymorphism of core 2 branching enzyme gene is associated with prostate cancer.
    Biochem Biophys Res Commun, 331(4): 958-63. [Abstract] [Full-text]
41. Interference with HH-GLI signaling inhibits prostate cancer.
    Trends Mol Med, 11(5): 199-203. [Abstract] [Full-text]
42. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB.
    J Pathol, 206(2): 214-9. [Abstract] [Full-text]
43. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    J Pathol, 206(2): 205-13. [Abstract] [Full-text]
44. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
    J Mol Recognit, 18(3): 225-35. [Abstract] [Full-text]
45. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Thromb Haemost, 93(5): 964-75. [Abstract] [Full-text]
46. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients.
    Urol Oncol, 23(1): 56-64. [Abstract] [Full-text]
47. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Urol Oncol, 23(1): 16-21. [Abstract] [Full-text]
48. PSA elevation during prostate cryosurgery and subsequent decline.
    Urol Oncol, 23(1): 8-11. [Abstract] [Full-text]
49. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Urol Oncol, 23(1): 1-7. [Abstract] [Full-text]
50. National cooperative group trials.
    Urology, 65(5): 23-9; discussion 29. [Abstract] [Full-text]
51. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
    Urology, 65(5): 18-22; discussion 22. [Abstract] [Full-text]
52. Future therapies in hormone-refractory prostate cancer.
    Urology, 65(5): 9-16; discussion 17. [Abstract] [Full-text]
53. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
    Urology, 65(5): 3-7; discussion 7-8. [Abstract] [Full-text]
54. Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer.
    Clin Biochem, 38(6): 558-71. [Abstract] [Full-text]
55. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis.
    Proc Natl Acad Sci U S A, 102(19): 6942-7. [Abstract] [Full-text]
56. Radical prostatectomy versus watchful waiting in early prostate cancer.
    N Engl J Med, 352(19): 1977-84. [Abstract] [Full-text]
57. Web-based virtual microscopy in teaching and standardizing Gleason grading.
    Hum Pathol, 36(4): 381-6. [Abstract] [Full-text]
58. Intensity-modulated radiotherapy for adenocarcinoma of the prostate: a point of view.
    Int J Radiat Oncol Biol Phys, 62(2): 454-9. [Abstract] [Full-text]
59. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Int J Radiat Oncol Biol Phys, 62(2): 448-53. [Abstract] [Full-text]
60. Erectile function after prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 62(2): 437-47. [Abstract] [Full-text]
61. Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer.
    Int J Radiat Oncol Biol Phys, 62(2): 426-36. [Abstract] [Full-text]
62. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
    Int J Radiat Oncol Biol Phys, 62(2): 418-25. [Abstract] [Full-text]
63. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI).
    Int J Radiat Oncol Biol Phys, 62(2): 406-17. [Abstract] [Full-text]
64. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
    Int J Radiat Oncol Biol Phys, 62(2): 397-405. [Abstract] [Full-text]
65. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.
    Int J Radiat Oncol Biol Phys, 62(2): 392-6. [Abstract] [Full-text]
66. Prostate cancer mediates osteoclastogenesis through two different pathways.
    Cancer Lett, 223(1): 121-8. [Abstract] [Full-text]
67. Does 'peer coaching' increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial.
    Fam Pract, 22(3): 253-65. [Abstract] [Full-text]
68. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.
    Cancer Cell, 7(5): 485-96. [Abstract] [Full-text]
69. Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy.
    Cancer Cell, 7(5): 408-9. [Abstract] [Full-text]
70. IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation.
    Cell Signal, 17(8): 929-39. [Abstract] [Full-text]
71. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Immunol Lett, 99(1): 85-93. [Abstract] [Full-text]
72. Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base.
    Brachytherapy, 4(2): 163-70. [Abstract] [Full-text]
73. Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants.
    Brachytherapy, 4(2): 146-53. [Abstract] [Full-text]
74. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy.
    Brachytherapy, 4(2): 141-5. [Abstract] [Full-text]
75. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.
    BJU Int, 95(9): 1336-43. [Abstract] [Full-text]
76. Is laparoscopic unilateral sural nerve grafting during radical prostatectomy effective in retaining sexual potency?
    BJU Int, 95(9): 1267-71. [Abstract] [Full-text]
77. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    BJU Int, 95(9): 1249-52. [Abstract] [Full-text]
78. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    BJU Int, 95(9): 1245-8. [Abstract] [Full-text]
79. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy.
    BJU Int, 95(9): 1237-44. [Abstract] [Full-text]
80. Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.
    BJU Int, 95(9): 1232-6. [Abstract] [Full-text]
81. Anatomical radical retropubic prostatectomy: 'curtain dissection' of the neurovascular bundle.
    BJU Int, 95(9): 1226-31. [Abstract] [Full-text]
82. Men, culture and hegemonic masculinity: understanding the experience of prostate cancer.
    Nurs Inq, 12(2): 87-97. [Abstract] [Full-text]
83. Interleukin-6 regulation of prostate cancer cell growth.
    J Cell Biochem, 95(3): 497-505. [Abstract] [Full-text]
84. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy.
    Cancer Gene Ther, 12(6): 572-8. [Abstract] [Full-text]
85. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Cancer Gene Ther, 12(6): 540-51. [Abstract] [Full-text]
86. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study.
    J Infect Dis, 191(12): 2008-11. [Abstract] [Full-text]
87. Apoptosis in non-tumorous adult human testis tissue. Comparison of so-called 'normal' testis tissues.
    Urol Int, 74(4): 349-54. [Abstract] [Full-text]
88. Should high-grade prostatic intraepithelial neoplasia change our approach to infravesical obstruction?
    Urol Int, 74(4): 332-6. [Abstract] [Full-text]
89. Association of vitamin D receptor gene polymorphism and risk of prostate cancer in India.
    Urol Int, 74(4): 315-8. [Abstract] [Full-text]
90. Efficacy of unilateral nerve sparing in radical perineal prostatectomy.
    Urol Int, 74(4): 308-14. [Abstract] [Full-text]
91. Management of prolonged urinary leakage at the urethro-vesical anastomosis.
    Urol Int, 74(4): 298-300. [Abstract] [Full-text]
92. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
    Urol Int, 74(4): 289-97. [Abstract] [Full-text]
93. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
    Clin Cancer Res, 11(10): 3930-8. [Abstract] [Full-text]
94. Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma.
    Clin Cancer Res, 11(10): 3905-14. [Abstract] [Full-text]
95. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
    Clin Cancer Res, 11(10): 3869-78. [Abstract] [Full-text]
96. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Clin Cancer Res, 11(10): 3854-61. [Abstract] [Full-text]
97. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.
    Clin Cancer Res, 11(10): 3743-9. [Abstract] [Full-text]
98. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells.
    Mol Cancer Ther, 4(5): 726-32. [Abstract] [Full-text]
99. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
    Endocr Rev, 26(3): 361-79. [Abstract] [Full-text]
100. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.
     J Biol Chem, 280(20): 19911-24. [Abstract] [Full-text]
101. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
     Int J Cancer, 115(5): 783-9. [Abstract] [Full-text]
102. Expression of the apoptotic calcium channel P2X7 in the glandular epithelium.
     J Mol Histol, 36(3): 159-65. [Abstract] [Full-text]
103. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
     Cancer Res, 65(10): 4448-57. [Abstract] [Full-text]
104. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
     Cancer Res, 65(10): 4309-19. [Abstract] [Full-text]
105. Functional epigenomics identifies genes frequently silenced in prostate cancer.
     Cancer Res, 65(10): 4218-27. [Abstract] [Full-text]
106. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer.
     Cancer Res, 65(10): 4126-33. [Abstract] [Full-text]
107. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
     Cancer Res, 65(10): 4097-100. [Abstract] [Full-text]
108. Intensity-modulated radiation therapy: emerging cancer treatment technology.
     Br J Cancer, 92(10): 1819-24. [Abstract] [Full-text]
109. Reduced risk of prostate cancer in men who are childless as compared to those who have fathered a child: a population based case-control study.
     Int J Cancer, 115(6): 994-7. [Abstract] [Full-text]
110. Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.
     Int J Cancer, 115(6): 911-6. [Abstract] [Full-text]
111. Biopsy of the mouse prostate.
     Lab Anim, 39(2): 215-20. [Abstract] [Full-text]
112. Raf-1 expression may influence progression to androgen insensitive prostate cancer.
     Prostate, 64(1): 101-7. [Abstract] [Full-text]
113. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
     Prostate, 64(1): 92-100. [Abstract] [Full-text]
114. Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families.
     Prostate, 64(1): 60-6. [Abstract] [Full-text]
115. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.
     Prostate, 64(1): 50-9. [Abstract] [Full-text]
116. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage.
     Prostate, 64(1): 40-9. [Abstract] [Full-text]
117. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
     Prostate, 64(1): 29-39. [Abstract] [Full-text]
118. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
     Prostate, 64(1): 20-8. [Abstract] [Full-text]
119. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
     Prostate, 64(1): 9-19. [Abstract] [Full-text]
120. Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.
     Prostate, 64(1): 1-8. [Abstract] [Full-text]
121. High dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and beta(1) integrin expression.
     Prostate, 64(1): 83-91. [Abstract] [Full-text]
122. Bi-directional interactions of prostate cancer cells and bone marrow endothelial cells in three-dimensional culture.
     Prostate, 64(1): 75-82. [Abstract] [Full-text]
123. Modulation of CXCL14 (BRAK) expression in prostate cancer.
     Prostate, 64(1): 67-74. [Abstract] [Full-text]
124. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
     Life Sci, 77(5): 562-77. [Abstract] [Full-text]
125. Quality of life in patients with localized prostate cancer.
     Urol Oncol, 23(3): 208-15. [Abstract] [Full-text]
126. Carcinosarcoma of the prostate with multiple metastases: case report and review of the literature.
     Urol Oncol, 23(3): 181-3. [Abstract] [Full-text]
127. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
     Urol Oncol, 23(3): 163-7. [Abstract] [Full-text]
128. Medical care cost of patients with prostate cancer.
     Urol Oncol, 23(3): 155-62. [Abstract] [Full-text]
129. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
     J Clin Oncol, 23(15): 3343-51. [Abstract] [Full-text]
130. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
     J Clin Oncol, 23(15): 3352-7. [Abstract] [Full-text]
131. Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer.
     Integr Cancer Ther, 4(2): 187-94. [Abstract] [Full-text]
132. Docetaxel administration schedule: from fever to tears? A review of randomised studies.
     Eur J Cancer, 41(8): 1117-26. [Abstract] [Full-text]
133. A community-based randomised controlled trial of three different educational resources for men about prostate cancer screening.
     Patient Educ Couns, 57(2): 168-82. [Abstract] [Full-text]
134. Equivocal impact of transplacental and lactational exposure to a food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, on prostate and colon lesion development in F344 rats.
     Cancer Lett, 224(1): 23-30. [Abstract] [Full-text]
135. Psychological distress in spouses of men treated for early-stage prostate carcinoma.
     Cancer, 103(11): 2412-8. [Abstract] [Full-text]
136. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
     Cancer, 103(11): 2280-6. [Abstract] [Full-text]
137. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T.
     Magn Reson Med, 53(6): 1268-74. [Abstract] [Full-text]
138. Cerebral ischemic events in patients with advanced lung or prostate cancer.
     Neuroepidemiology, 24(4): 230-6. [Abstract] [Full-text]
139. Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence.
     Oncogene, 24(23): 3748-58. [Abstract] [Full-text]
140. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.
     Oncogene, 24(23): 3847-52. [Abstract] [Full-text]
141. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
     Cancer Immunol Immunother, 54(7): 694-702. [Abstract] [Full-text]
142. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
     Osteoporos Int, 16(6): 707-11. [Abstract] [Full-text]
143. Aryl hydrocarbon exposure induces expression of MMP-9 in human prostate cancer cell lines.
     Cancer Lett, 225(1): 159-66. [Abstract] [Full-text]
144. Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors.
     Cancer Lett, 225(1): 35-40. [Abstract] [Full-text]
145. Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity-modulated radiotherapy.
     Med Dosim, 30(2): 97-103. [Abstract] [Full-text]
146. Dose verification with Monte Carlo technique for prostate brachytherapy implants with (125)I sources.
     Med Dosim, 30(2): 85-91. [Abstract] [Full-text]
147. Correction of systematic setup errors in prostate radiation therapy: how many images to perform?
     Med Dosim, 30(2): 76-84. [Abstract] [Full-text]
148. IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization.
     Med Dosim, 30(2): 69-75. [Abstract] [Full-text]
149. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.
     Int J Cancer, 116(2): 226-35. [Abstract] [Full-text]
150. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial.
     Int J Cancer, 116(2): 182-6. [Abstract] [Full-text]
151. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer.
     Int J Cancer, 116(2): 291-6. [Abstract] [Full-text]
152. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer.
     Int J Cancer, 116(2): 174-81. [Abstract] [Full-text]
153. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
     Prostate, 64(2): 209-16. [Abstract] [Full-text]
154. Susceptibility of Lobund-Wistar x Copenhagen hybrid rats to autochthonous prostate carcinogenesis.
     Prostate, 64(2): 203-8. [Abstract] [Full-text]
155. Importance of TURP in diagnosing prostate cancer in men with multiple negative biopsies.
     Prostate, 64(2): 200-2. [Abstract] [Full-text]
156. Increased phospho-AKT is associated with loss of the androgen receptor during the progression of N-methyl-N-nitrosourea-induced prostate carcinogenesis in rats.
     Prostate, 64(2): 186-99. [Abstract] [Full-text]
157. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue.
     Prostate, 64(2): 149-59. [Abstract] [Full-text]
158. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
     Prostate, 64(2): 139-48. [Abstract] [Full-text]
159. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.
     Prostate, 64(2): 160-7. [Abstract] [Full-text]
160. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk.
     Prostate, 64(2): 168-74. [Abstract] [Full-text]
161. Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study.
     Prostate, 64(2): 109-15. [Abstract] [Full-text]
162. Use of thymosin beta15 as a urinary biomarker in human prostate cancer.
     Prostate, 64(2): 116-27. [Abstract] [Full-text]
163. Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma.
     Prostate, 64(2): 128-38. [Abstract] [Full-text]
164. Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer.
     Nutrition, 21(6): 686-90. [Abstract] [Full-text]
165. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines.
     Eur Urol, 47(6): 895-900. [Abstract] [Full-text]
166. Prostate cancer incidence in guadeloupe, a French Caribbean archipelago.
     Eur Urol, 47(6): 769-72. [Abstract] [Full-text]
167. Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome.
     Eur Urol, 47(6): 761-8. [Abstract] [Full-text]
168. Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?
     Eur Urol, 47(6): 756-60. [Abstract] [Full-text]
169. Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment.
     Eur Urol, 47(6): 729-35. [Abstract] [Full-text]
170. DNA binding specificity and cytotoxicity of novel antitumor agent Ge132 derivatives.
     Bioorg Med Chem Lett, 15(12): 2962-5. [Abstract] [Full-text]
171. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
     Biochem Biophys Res Commun, 332(3): 800-7. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.